Acipimox does not augment thallium-201 redistribution in the fasting state
- 19 Downloads
Abstract
Background
Recently oral glucose loading and a thallium-glucose insulin infusion have been used to augment myocardial uptake of thallium-201 (Tl-201). Acipimox is a nicotinic-acid derivative that reduces serum free fatty acid (FFA) levels and enhances myocardial glucose uptake. This study was performed to assess the effects of acipimox on Tl-201 redistribution.
Methods
Fourteen patients with coronary artery disease underwent 2 successive Tl-201 perfusion studies. Stress was performed by adenosine coupled with ergometer exercise. Patients received either 500 mg of acipimox or placebo immediately after stress, and images were acquired. Redistribution imaging was carried out after 4 hours. Patients returned after 7 to 14 days for a repeat stress protocol, receiving the alternate test article. Both studies were carried out under identical conditions with identical medication with the patient in the fasting state. Image analysis was conducted quantitatively with polar plots and by using segmental uptake as a percentage of maximal counts with a 9-segment model.
Results
There were no significant differences between the acipimox and placebo arms of the study of hemodynamic parameters. On polar plot analysis, there were no differences between acipimox and placebo for mean values of stress defect extent (97±16.1 vs 96.5±18.8 pixels), defect severity (532.2±120 vs 537±133.9 standard deviations [SDs]), for defect reversibility (61.7±18 vs 55.4±15.3 SDs), and percentage reversibility (21.2%±5.5% vs 19.2%±5.8%), respectively. Similarly, on segmental uptake analysis there was no significant difference between the acipimox and placebo arms with regard to the proportion of segments classified as normal, fixed defect, reversible defect, or reverse redistribution.
Conclusion
Although acipimox has been shown to augment myocardial glucose uptake and myocardial glucose uptake has been shown to improve cellular uptake of Tl-201, in the fasting state acipimox does not enhance the redistribution after stress. This may be because serum insulin levels are not increased by acipimox, and insulin is instrumental in enhancing the joint transport of glucose and Tl-201 into myocytes.
Key Words
Thallium redistribution acipimox insulin glucosePreview
Unable to display preview. Download preview PDF.
References
- 1.Kiat H, Berman DS, Maddahi J, et al. Late reversibility of tomographic myocardial thallium-201 defects: an accurate marker of myocardial viability. J Am Coll Cardiol 1988;12:1456–63.PubMedGoogle Scholar
- 2.Kayden DS, Sigal S, Soufer R, et al. Thallium-201 for assessment of myocardial viability: quantitative comparison of 24 hour redistribution imaging with imaging after reinjection at rest. J Am Coll Cardiol 1991;18:1480–6.PubMedGoogle Scholar
- 3.Ragosta M, Beller GA, Watson DD, et al. Quantitative planar rest-redistribution Tl-201 imaging in detection of myocardial viability and prediction of improvement in left ventricular function after coronary bypass surgery in patients with severely depressed left ventricular function. Circulation 1993; 87:1630–41.PubMedGoogle Scholar
- 4.He ZX, Darcourt J, Guignier A, et al. Nitrates improve detection of ischaemic but viable myocardium by thallium-201, reinjection SPECT. J Nucl Med 1993;34:1472–7.PubMedGoogle Scholar
- 5.Perlmutter NS, Wilson RA, Angello DA, et al. Ribose facilitates thallium-201 redistribution in patients with coronary artery disease. J Nucl Med 1991;32:193–200.PubMedGoogle Scholar
- 6.Lucignani G, Paolini G, Landoni C, et al. Presurgical identification of hibernating myocardium by combined use of technetium-99m hexokinase 2-methoxyisobutylisonitrile single photon emission tomography and fluorine-18 fluoro-2-deoxy-d-glucose positron emission tomography in patients with coronary artery disease. Eur J Nucl Med 1992;19:874–81.PubMedCrossRefGoogle Scholar
- 7.Marshall RC, Tillisch JH, Phelps ME, et al. Identification and differentiation of resting myocardial ischemia and infarction in man with positron computed tomography ZSF-labelled, fluorodeoxyglucose and N-13 ammonia. Circulation 1983;67:766–78.PubMedGoogle Scholar
- 8.Di Carli M, Davison M, Little R, et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol 1994;73:527–33.PubMedCrossRefGoogle Scholar
- 9.Bax JJ, Cornel JH, Visser FC, et al. Prediction of recovery of myocardial dysfunction after revascularization. Comparison of fluorine-18 fluorodeoxyglucose/thallium-201 SPECT, thallium-201 stress-reinjection SPECT and dobutamine echocardiography. J Am Coll Cardiol 1996; 28:558–64.PubMedCrossRefGoogle Scholar
- 10.Knuuti MJ, Nuutila P, Ruotsalainen U, et al. Euglycemic hyperinsulinemic clamp and oral glucose load in stimulating myocardial glucose utilization during positron emission tomography. J Nucl Med 1992;33:1255–62.PubMedGoogle Scholar
- 11.Mussatti L, Maggi E, Moro E, Valzeli G, Tamassia V. Bioavailability and pharmacokinetics in man of acipimox, a new antilipolytic and hypolipaemic agent. J Int Med Res 1981;9:381–6.Google Scholar
- 12.Eriksson S, Eriksson M, Berglund L, et al. Metabolism of plasma low density lipoproteins in familial combined hyperlipidemia: effect of acipimox. J Intern Med 1992;232:313–20.PubMedCrossRefGoogle Scholar
- 13.Knuuti MJ, Yki-Jarvinen H, Voipo-Pulkki LM, et al. Enhancement of myocardial [fluorine-18]fluorodeoxyglucose uptake by a nicotinic acid derivative. J Nucl Med 1994;35:989–98.PubMedGoogle Scholar
- 14.Bax JJ, Veening MA, Visser FC, et al. Image quality of FDG SPECT using a nicotinic acid derivative. J Nucl Cardiol 1997;4:(Suppl)S22.CrossRefGoogle Scholar
- 15.Chiba H, Kusuoka H, Ohno J, et al. Glucose-loading thallium-201 myocardial SPECT. J Nucl Med 1997;38:573–7.PubMedGoogle Scholar
- 16.Tartagni F, Fallani F, Corbelli C, et al. Detecting hibernated myocardium with SPECT and thallium-glucose-insulin infusion. J Nucl Med 1995;36:1377–83.PubMedGoogle Scholar
- 17.Eitzmann D, Al-Alouar Z, Kanter HL, et al. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol 1992;20:559–65.CrossRefGoogle Scholar
- 18.Choi Y, Brunken R, Hawkins R, et al. Determinants of myocardial glucose utilization assessed with dynamic PDG PET [abstract]. Circulation 1991;84:II-425.Google Scholar
- 19.Berry J, Baker J, Pieper K, et al. The effect of the metabolic milieu on cardiac PET imaging using fluorine-18-deoxyglucose and nitrogen-13-ammonia in normal volunteers. J Nucl Med 1991;32:1518–25.PubMedGoogle Scholar
- 20.Wilson RA, Okada RD, Strauss HW, et al. Effect of glucose-insulin-potassium infusion on thallium myocardial clearance. Circulation 1983;68:203–9.PubMedGoogle Scholar
- 21.Angello DA, Wilson RA, Palac RT. Effect of eating on 201Tl myocardial redistribution after myocardial ischemia. Am J Cardiol 1987;60:528–33.PubMedCrossRefGoogle Scholar
- 22.Monti LD, Lucignani G, Landoni C, et al. Myocardial glucose uptake evaluated by positron emission tomography and fluorodeoxyglucose during hyperglycemic clamp in IDDM patients: role of free fatty acid and insulin levels. Diabetes 1995;44:537–42.PubMedCrossRefGoogle Scholar
- 23.Worm D, Henriksen JE, Vaag A, et al. Pronounced blood glucose lowering effect of the antilipolytic drug acipimox in non-insulin dependent diabetes mellitus patients during a 3-day intensified treatment period. J Clin Endocrinol Metab 1994;78:717–21.PubMedCrossRefGoogle Scholar